top of page

Regenerative Therapeutics

 

​

Discovery platform to develop metabolic therapeutics to treat chronic and/or aging diseases.

About Us

 

 

Tixupharma is an innovative medical device company based in Milan, established in 2013 as academic spin-out and consolidated in 2019 to pioneer untapped regenerative pathways in age-related and traumatic diseases. 

 

​Form 2026 onward activities will re-split into two entities: Tixupharma Srl to continue the development of substance-based medical device under a new management; whilst Tixupharma of Carlo Ghisalberti will focus on aesthetic medicine and advanced cosmeceutical solutions.

Mission

 

 

Worldwide, millions of people suffer from unmet degenerative diseases requiring effective therapeutics.

​​

Tixupharma Srl's mission is to develop first-in-class therapies to treat such diseases by leveraging mechanotransduction driving-forces starting from unmet women's healthcare needs.

​

Other emerging aesthetic issues of the aging population will be managed by a separate entity, who just continues a tradition of tissue regeneration in a non-therapeutic regulatory frame.

Regenerative Approach

​​​

The initiatives exploit non-pharmacologic, autocrine signaling pathways to advance either therapeutics (medical device) for unmet or undeserved medical needs; or the opportunities in aesthetic medicine and female wellbeing. ​​​​

2025 by TIXUPHARMA. 

  • LinkedIn
bottom of page